81 related articles for article (PubMed ID: 28245413)
1. [Research Progress in Transgenic Animal Models of Chronic Lymphocytic Leukemia -Review].
Wu FT; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):259-263. PubMed ID: 28245413
[TBL] [Abstract][Full Text] [Related]
2. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
3. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
4. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
5. Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy.
Simonetti G; Bertilaccio MT; Ghia P; Klein U
Blood; 2014 Aug; 124(7):1010-9. PubMed ID: 25006127
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemia: molecular genetics and animal models.
Pekarsky Y; Calin GA; Aqeilan R
Curr Top Microbiol Immunol; 2005; 294():51-70. PubMed ID: 16323427
[TBL] [Abstract][Full Text] [Related]
7. Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia.
Fernandez Botana I; Gonder S; Klapp V; Moussay E; Paggetti J
Methods Cell Biol; 2024; 188():109-129. PubMed ID: 38880520
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
Enzler T; Kater AP; Zhang W; Widhopf GF; Chuang HY; Lee J; Avery E; Croce CM; Karin M; Kipps TJ
Blood; 2009 Nov; 114(20):4469-76. PubMed ID: 19755673
[TBL] [Abstract][Full Text] [Related]
9. The TCL1 mouse as a model for chronic lymphocytic leukemia.
Hamblin TJ
Leuk Res; 2010 Feb; 34(2):135-6. PubMed ID: 19726084
[TBL] [Abstract][Full Text] [Related]
10. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
11. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
[TBL] [Abstract][Full Text] [Related]
12. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.
Hofbauer JP; Heyder C; Denk U; Kocher T; Holler C; Trapin D; Asslaber D; Tinhofer I; Greil R; Egle A
Leukemia; 2011 Sep; 25(9):1452-8. PubMed ID: 21606964
[TBL] [Abstract][Full Text] [Related]
13. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
14. Evidence for Non-Cancer-Specific T Cell Exhaustion in the Tcl1 Mouse Model for Chronic Lymphocytic Leukemia.
Parigger T; Gassner FJ; Scherhäufl C; Bakar AA; Höpner JP; Hödlmoser A; Steiner M; Catakovic K; Geisberger R; Greil R; Zaborsky N
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206229
[TBL] [Abstract][Full Text] [Related]
15. A role for IRF4 in the development of CLL.
Shukla V; Ma S; Hardy RR; Joshi SS; Lu R
Blood; 2013 Oct; 122(16):2848-55. PubMed ID: 23926303
[TBL] [Abstract][Full Text] [Related]
16. Loss of p53 and altered miR15-a/16-1MCL-1 pathway in CLL: insights from TCL1-Tg:p53(-/-) mouse model and primary human leukemia cells.
Liu J; Chen G; Feng L; Zhang W; Pelicano H; Wang F; Ogasawara MA; Lu W; Amin HM; Croce CM; Keating MJ; Huang P
Leukemia; 2014 Jan; 28(1):118-28. PubMed ID: 23608884
[TBL] [Abstract][Full Text] [Related]
17. Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Zaborsky N; Gassner FJ; Höpner JP; Schubert M; Hebenstreit D; Stark R; Asslaber D; Steiner M; Geisberger R; Greil R; Egle A
Leukemia; 2019 Apr; 33(4):957-968. PubMed ID: 30262843
[TBL] [Abstract][Full Text] [Related]
18. Animal models for chronic lymphocytic leukemia.
Pekarsky Y; Zanesi N; Aqeilan RI; Croce CM
J Cell Biochem; 2007 Apr; 100(5):1109-18. PubMed ID: 17131382
[TBL] [Abstract][Full Text] [Related]
19. Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.
Kress CL; Konopleva M; Martínez-García V; Krajewska M; Lefebvre S; Hyer ML; McQueen T; Andreeff M; Reed JC; Zapata JM
PLoS One; 2007 Jun; 2(6):e559. PubMed ID: 17593960
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.
Kriss CL; Pinilla-Ibarz JA; Mailloux AW; Powers JJ; Tang CH; Kang CW; Zanesi N; Epling-Burnette PK; Sotomayor EM; Croce CM; Del Valle JR; Hu CC
Blood; 2012 Aug; 120(5):1027-38. PubMed ID: 22692508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
